# GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer

> **NCT06235242** · NA · TERMINATED · sponsor: **Grit Biotechnology** · enrollment: 2 (actual)

## Conditions studied

- Adult
- Non-small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** GT201 injection in combination with teraplizumab injection

## Key facts

- **NCT ID:** NCT06235242
- **Lead sponsor:** Grit Biotechnology
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-02-02
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** The study was terminated from a business perspective.
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06235242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06235242, "GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06235242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*